
German pharmaceutical giant Bayer’s shares jumped 10.5% on the London Stock Exchange on Tuesday morning following the company experiencing higher demand for its new cancer and kidney drugs in the first quarter of 2025.
Earnings before interest, taxes, depreciation and amortisation (EBITDA) before special items was €4.1 billion for the first quarter of 2025. Although this was a 7.4% fall from the corresponding quarter a year ago, it was still above market expectations of €3.9bn, according to Bloomberg.